The right to treatment of children with refractory epileptic syndromes

challenges and opportunities in Cannabidiol accessing

Abstract

The use of cannabidiol in children with refractory epileptic syndromes is a subject that has generated heated debates in the medical and legal community. Although cannabidiol is a substance found in the marijuana plant, its use for medicinal purposes has been studied and approved in several countries, including Brazil. However, despite its proven eff ectiveness in treating some diseases, access to this treatment is still a challenge for many families, who face bureaucratic and legal barriers to obtaining medication. Given this, the question is what is the impact of bureaucratic and legal barriers on the use of cannabidiol in children with refractory epileptic syndromes, and how to guarantee the right of access to this treatment in a safe and eff ective way? The primary hypothesis is that the use of cannabidiol in children with refractory epileptic syndromes is eff ective and can provide a signifi cant improvement in the quality of life of these patients. The general objective of this article is to analyze the challenges and opportunities in the right of access to cannabidiol treatment in children with refractory epileptic syndromes. It was noticed that bureaucratic and legal barriers in the use of cannabidiol in children with refractory epileptic syndromes have a signifi cant impact, making access to this treatment diffi cult. This can result in delays in the initiation of treatment, deprivation of the therapeutic benefi ts of cannabidiol, and increased distress for these children and their families. In addition, it is essential to promote the awareness and training of health professionals about the benefi ts and risks of cannabidiol, so that they can make informed and informed decisions when prescribing this treatment.